A Phase 2/3 interventional study of masitinib 3 mg and masitinib 6.0 mg in Rheumatoid Arthritis (RA), sponsored by AB Science. Terminated at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-17.
Sponsored by AB Science · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Arthritis, Rheumatoid with a site in Czechia — 3 open to participants now, 9 under way, 3 of them phase 3. Arthritis, Rheumatoid · Czechia.
Among the 198 studies in Arthritis, Rheumatoid with a site in Czechia, this one is the 94th largest by enrollment of the 190 interventional ones that give a count, is one of 14 that started in 2011, is one of 2 in phase 2/3, and was the 82nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 198 studies in Arthritis, Rheumatoid with a site in Czechia are open now. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Czechia, United States, Australia and 7 more countries
Ages 18+
AbbVie · Sites in Czechia, United States, Canada and 9 more countries
Ages 18+
Azienda Unita Sanitaria Locale di Piacenza · Sites in Czechia, Italy
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 97 · Phase 3 72 · Phase 4 14
First in 2000; this study’s year is marked. 14 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 323 across the 190 interventional studies, 301 across the 8 observational. Of the 188 that completed or were terminated, 139 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
194 of 198 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Rheumatoid with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 198 studies in Arthritis, Rheumatoid with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
masitinib 3 mg/kg/day, tablets, orally, twice a day
Drug: masitinib 3 mg · Drug: Placebo (methotrexate)
masitinib 6.0 mg/kg/day, tablets, orally, twice a day
Drug: masitinib 6.0 mg · Drug: Placebo (methotrexate)
methotrexate at the dose of 15 or 20 mg per week
Drug: methotrexate · Drug: Placebo (masitinib)
Also known as: AB1010
Also known as: AB1010
ACR50
Time frame: week 24
ACR
Time frame: week 12
The record gives a start of Jul 2011, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib